8A, we generated various constructs carrying only subsets of these substitutions and initially analyzed their ability to stimulatemim-1enhancer activity in reporter gene experiments. non-coding RNA. Furthermore, our data show that the oncogenic mutations of AMV have disrupted the ability of v-Myb to induce remodeling of chromatin structure at themim-1enhancer. Together, our results demonstrate for the first time directly that Myb induces alterations of the nucleosomal organization at a relevant target site and provide new insight into the functional consequences of the oncogenic amino acid substitutions. == Introduction == Myb proteins constitute a family of transcription factors playing key roles during proliferation and differentiation of various cell types (1,2). v-Myb was originally identified as the protein encoded by the oncogene v-mybof avian myeloblastosis virus (AMV)3(3). v-mybis a truncated and mutated derivative of chicken c-myb, which is highly expressed in immature hematopoietic cells and is down-regulated during terminal differentiation. A large body of work has demonstrated that c-mybplays a crucial role in the development of the hematopoietic system; in addition, deregulation of c-mybhas been implicated in the development of colon and breast cancer as well as leukemia (4). v-Myb and c-Myb are DNA-binding proteins that recognize a specific sequence motif (5) and activate promoters containing this motif (69). A variety of approaches has been used to identify Myb target genes, such as differential screening of cells transformed by a temperature-sensitive mutant of v-Myb (7), differential display of RNA from cells expressing estrogen-inducible or dominant-interfering versions of v-Myb or c-Myb (1012) or microarray-based assays of cells overexpressing different Myb family members (13,14). Although a growing KRAS G12C inhibitor 16 number of Myb target genes are now known, how they contribute to the biological effects of Myb is not fully understood. Myb sequences have been transduced into two retroviruses, AMV and E26. The oncogenic potential of v-Myb is mainly caused by N- and C-terminal truncations that have occurred during retroviral transduction. In addition, the v-Myb protein of AMV harbors Mouse monoclonal to Cyclin E2 several amino acid substitutions that were acquired during the passage of the virus and strongly enhance its oncogenic potential (15). These oncogenic substitutions have raised considerable interest because they exert drastic effects on the activity of v-Myb and the spectrum of its target genes (14,16). Some of the oncogenic substitutions are located in the DNA binding domain and affect the interaction of v-Myb with DNA (17,18) and other proteins (1921). Several amino acid substitutions, which are located around the transactivation domain of v-Myb, have also been implicated in defining the spectrum of v-Myb target genes (16); however, how they exert their effects is unknown. The chickenmim-1gene is one of the most thoroughly studied Myb target genes. Within the hematopoietic system,mim-1is only KRAS G12C inhibitor 16 transcribed in myelomonocytic cells and reaches extremely high expression levels (7). Because of its lineage-restricted expression and the strong activation by Myb, themim-1gene is an interesting model to study how Myb activates its target genes. Previous work has shown that themim-1promoter harbors Myb and C/EBP binding sites and that Myb synergizes with C/EBP family members to activatemim-1expression (22,23). Additional insight intomim-1gene activation was provided by the identification of a Myb-responsive enhancer located 2-kb upstream of themim-1promoter (24). We have recently shown that KRAS G12C inhibitor 16 the transcription factor C/EBP induces opening of the compact chromatin structure at the enhancer in a step preceding the transcription of the gene (25). These observations suggested that themim-1enhancer plays an important role during the activation of the gene and have mademim-1an interesting model to study the stepwise activation of a gene by Myb. Here, we show that Myb induces extensive remodeling of the nucleosomal architecture at the enhancer. Surprisingly, we found that themim-1enhancer region also harbors a Myb-inducible promoter which drives transcription of an apparently non-coding RNA. Furthermore, we show.